FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
Background and rationale: Among the key players in the pathogenesis of Amyotrophic Lateral Sclerosis (ALS), microglia and T regulatory lymphocytes (Treg) are candidate cells for modifying the course of the disease. The gut microbiota (GM) acts by shaping immune tolerance and regulating the Treg number and suppressive function, besides circulating neuropeptides and other immune cells that play in concert through the gut-brain axis. Previous mouse models have shown an altered enteric flora in early stage ALS, pointing to a possible GM role in ALS pathogenesis. Fecal Microbial Transplantation (FMT) is a well-known therapeutic intervention used to re-establish the proper microenvironment and to modulate enteric and systemic immunity. Methods: We are going to perform a multicenter randomized double-blind clinical trial employing FMT as a therapeutic intervention for ALS patients (NCT0376632). 42 ALS patients, at an early stage, will be enrolled with a 2:1 allocation ratio (28 FMT-treated patients versus 14 controls). Study duration will be 12 months per patient. Three endoscopic procedures for intestinal biopsies in FMT and control groups are predicted at baseline, month 6 and month 12; at baseline and at month 6 fresh feces from healthy donors will be infused at patients in the intervention arm. The primary outcome is a significant change in Treg number between FMT-treated patients and control arm from baseline to month 6. Secondary outcomes include specific biological aims, involving in-depth analysis of immune cells and inflammatory status changes, central and peripheral biomarkers of ALS, besides comprehensive analysis of the gut, saliva and fecal microbiota. Other secondary aims include validated clinical outcomes of ALS (survival, forced vital capacity, and modifications in ALSFRS-R), besides safety and quality of life. Expected results: We await FMT to increase Treg number and suppressive functionality, switching the immune system surrounding motorneurons to an anti-inflammatory, neuroprotective status. Extensive analysis on immune cell populations, cytokines levels, and microbiota (gut, fecal and saliva) will shed light on early processes possibly leading the degenerative ALS course. Conclusions: This is the first trial with FMT as a potential intervention to modify immunological response to ALS and disease progression at an early stage.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Duodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708 · cited 1×
“FMT has been approved for the treatment of this condition, for which it has had unanimously excellent results (24, 37, 38).”
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Host microbiota constantly control maturation and function of microglia in the CNS
Erny, D., Hrabě de Angelis, A. L., Jaitin, D., Wieghofer, P., Staszewski, O., David, E., Keren-Shaul, H., Mahlakoiv, T., Jakobshagen, K., Buch, T., et al. (2015) · Nature Neuroscience · doi:10.1038/nn.4030 · Cited by 3,569
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Round, J. L., & Mazmanian, S. K. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909122107 · Cited by 2,233 · cited 1×
“Some commensal bacteria can induce Tregs development and FMT determine Tregs’ increase (54).”
BackgroundGut microbiota are related to Parkinson's disease and clinical phenotype
Scheperjans, F., Aho, V., Pereira, P. A. B., Koskinen, K., Paulin, L., Pekkonen, E., Haapaniemi, E., Kaakkola, S., Eerola‐Rautio, J., Pohja, M., et al. (2015) · Movement Disorders · doi:10.1002/mds.26069 · Cited by 1,968
Interactions between the microbiota, immune and nervous systems in health and disease
Fung, T. C., Olson, C. A., & Hsiao, E. Y. (2017) · Nature Neuroscience · doi:10.1038/nn.4476 · Cited by 1,900
Onset and Progression in Inherited ALS Determined by Motor Neurons and Microglia
Boillée, S., Yamanaka, K., Lobsiger, C. S., Copeland, N. G., Jenkins, N. A., Kassiotis, G., Kollias, G., & Cleveland, D. W. (2006) · Science · doi:10.1126/science.1123511 · Cited by 1,623
Research works printed but not linked: 31
- Oskarsson, 2018, Amyotrophic lateral sclerosis: an update for 2018, Mayo Clin Proc., 93, 1617, 10.1016/j.mayocp.2018.04.007 · DOI · Paper page
- Rossi, 2016, Old versus new mechanisms in the pathogenesis of ALS, Brain Pathol., 26, 276, 10.1111/bpa.12355 · DOI
- Geloso, 2017, The dual role of microglia in ALS: mechanisms and therapeutic approaches, Front Aging Neurosci., 9, 242, 10.3389/fnagi.2017.00242 · DOI · Paper page
- Tiemessen, 2007, CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages, PNAS., 104, 19446, 10.1073/pnas.0706832104 · DOI · Paper page
- Liu, 2011, Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice, Immunol Cell Biol., 89, 130, 10.1038/icb.2010.70 · DOI · Paper page
- Schetters, 2018, Neuroinflammation: microglia and T cells get ready to tango, Front Immunol., 8, 1905, 10.3389/fimmu.2017.01905 · DOI · Paper page
- Beers, 2011, Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice and correlate with disease progression in patients with amyotrophic lateral sclerosis, Brain., 134, 1293, 10.1093/brain/awr074 · DOI · Paper page
- Henkel, 2013, Regulatory T-lymphocytes mediate amyotrophic lateral sclerosis progression and survival, EMBO Mol Med., 5, 64, 10.1002/emmm.201201544 · DOI · Paper page
- Thonhoff, 2018, Expanded autologous regulatory T-lymphocyte infusions in ALS: a phase I, first-in-human study, Neurol Neuroimmunol Neuroinflamm., 5, e465, 10.1212/NXI.0000000000000465 · DOI · Paper page
- Backhed, 2005, Host-bacterial mutualism in the human intestine, Science., 307, 1915, 10.1126/science.1104816 · DOI · Paper page
- Conway, 1997, Development of intestinal microbiota, 3, 10.1007/978-1-4757-0322-1_1 · DOI
- Eckburg, 2005, Diversity of the human intestinal microbial flora, Science., 308, 1635, 10.1126/science.1110591 · DOI · Paper page
- Sabel, 2003, Spatial clustering of amyotrophic lateral sclerosis in Finland at place of birth and place of death, Am J Epidemiol., 157, 898, 10.1093/aje/kwg090 · DOI · Paper page
- Khanna, 2018, Microbiota replacement therapies: innovation in gastrointestinal care, Clin Pharmacol Ther., 103, 102, 10.1002/cpt.923 · DOI · Paper page
- Kimura, 2006, Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS, Neurology., 66, 265, 10.1212/01.wnl.0000194316.91908.8a · DOI · Paper page
- Mantovani, 2009, Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process, J Neuroimmunol., 210, 73, 10.1016/j.jneuroim.2009.02.012 · DOI · Paper page
- Baxter, 2016, Adverse events in faecal microbiota transplant: a review of the literature, J Hosp Infect., 92, 117, 10.1016/j.jhin.2015.10.024 · DOI · Paper page
- Wang, 2016, Systematic review: adverse events of fecal microbiota transplantation, PLoS ONE., 11, e0161174, 10.1371/journal.pone.0161174 · DOI · Paper page
- Brandt, 2015, Fecal microbiota transplant: respice, adspice, prospice, J Clin Gastroenterol., 49, 65, 10.1097/MCG.0000000000000346 · DOI
- Eiseman, 1958, Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis, Surgery., 44, 854
- Schwan, 1983, Relapsing clostridium difficile enterocolitis cured by rectal infusion of homologous faeces, Lancet., 2, 845, 10.1016/S0140-6736(83)90753-5 · DOI · Paper page
- Cammarota, 2015, Randomised clinical trial: faecal microbiota transplantation by colonoscopy vs, . Aliment Pharmacol Ther., 41, 835, 10.1111/apt.13144 · DOI · Paper page
- Fang, 2016, Potential role of gut microbiota and tissue barriers in Parkinson's disease and amyotrophic lateral sclerosis, Int J Neurosci., 126, 771, 10.3109/00207454.2015.1096271 · DOI · Paper page
- Scheperjans, 2016, Can microbiota research change our understanding of neurodegenerative diseases?, Neurodegener Dis Manage, 6, 81, 10.2217/nmt-2015-0012 · DOI
- Kuraszkiewicz, 2018, Are there modifiable environmental factors related to amyotrophic lateral sclerosis?, Front Neurol, 9, 220, 10.3389/fneur.2018.00220 · DOI
- Tremlett, 2016, Gut microbiota composition and relapse risk in pediatric MS: a pilot study, J Neurol Sci., 363, 153, 10.1016/j.jns.2016.02.042 · DOI · Paper page
- Kadowaki, 2016, Gut environment-induced intraepithelial autoreactive CD4(+) T cells suppress central nervous system autoimmunity via LAG-3, Nat Commun., 7, 11639, 10.1038/ncomms11639 · DOI · Paper page
- Fang, 2016, Evaluation of the microbial diversity in amyotrophic lateral sclerosis using high-throughput sequencing, Front Microbiol., 7, 1479, 10.3389/fmicb.2016.01479 · DOI · Paper page
- Mazzini, 2018, Potential role of gut microbiota in ALS pathogenesis and possible novel therapeutic strategies, J Clin Gastroenterol., 52, S68, 10.1097/MCG.0000000000001042 · DOI · Paper page
- Piccione, 2015, Autonomic system and amyotrophic lateral sclerosis, Muscle Nerve., 51, 676, 10.1002/mus.24457 · DOI
- Pecere, 2015, Letter: faecal microbiota transplantation in combination with fidaxomicin to treat severe complicated recurrent Clostridium difficile infection, Aliment Pharmacol Ther., 42, 1030, 10.1111/apt.13362 · DOI
Cited by
Mandrioli, J., D’Amico, R., Zucchi, E., Gessani, A., Fini, N., Fasano, A., Caponnetto, C., Chiò, A., Dalla Bella, E., Lunetta, C., et al. (2018) · Medicine · doi:10.1097/md.0000000000011119 · Cited by 128
Self-citationThe gut microbiome: a key player in the complexity of amyotrophic lateral sclerosis (ALS)
Boddy, S. L., Giovannelli, I., Sassani, M., Cooper-Knock, J., Snyder, M. P., Segal, E., Elinav, E., Barker, L. A., Shaw, P. J., & McDermott, C. J. (2021) · BMC Medicine · doi:10.1186/s12916-020-01885-3 · Cited by 127
Aberrant enteric neuromuscular system and dysbiosis in amyotrophic lateral sclerosis
Zhang, Y., Ogbu, D., Garrett, S., Xia, Y., & Sun, J. (2021) · Gut Microbes · doi:10.1080/19490976.2021.1996848 · Cited by 61
A Gut Feeling in Amyotrophic Lateral Sclerosis: Microbiome of Mice and Men
Martin, S., Battistini, C., & Sun, J. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.839526 · Cited by 54
“To treat gut microbiota dysbiosis through microbiota restoration would have the potential to interfere and slow ALS progression (Mandrioli et al., 2019).”
BackgroundGut microbiome and amyotrophic lateral sclerosis: a systematic review of current evidence
Sun, J., Huang, T., Debelius, J. W., & Fang, F. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13336 · Cited by 43
Metadata
- Authors
- Mandrioli, J., Amedei, A., Cammarota, G., Niccolai, E., Zucchi, E., D'Amico, R., Ricci, F., Quaranta, G., Spanu, T., & Masucci, L.
- Venue
- Frontiers in Neurology
- Publisher
- Frontiers Media SA
- Published
- 2019-09-20
- Volume
- 10
- Pages
- 1021-1021
- ISSN
- 1664-2295 (ISSN-L)
- OpenAlex
- W2973416631
- Cited by
- 78
- References
- 32
- FWCI
- 2.51
- Type
- journal article
- Language
- en
- Open access
- gold
- Funders
- Agenzia Italiana del Farmaco, Ministero della Salute (RF-2016-02361616)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. https://app.cochat.ai/papers/10.3389/fneur.2019.01021
- The paper
- Mandrioli, J., Amedei, A., Cammarota, G., Niccolai, E., Zucchi, E., D'Amico, R., Ricci, F., Quaranta, G., Spanu, T., & Masucci, L. (2019). FETR-ALS Study Protocol: A Randomized Clinical Trial of Fecal Microbiota Transplantation in Amyotrophic Lateral Sclerosis. Frontiers in Neurology. https://doi.org/10.3389/fneur.2019.01021
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.